OSL

15.4%

1.5¢ oncosil medical ltd

OSL Chart, page-59

First 59 Last

Share
Profile

Follow
Wedgeman7

2,010 Posts.

615

01/10/20

12:12

Post #: 47773280
Share

Originally posted by Gekkowolf: ↑

Hi Hyper

Yes it was a bit of fun. To be absolutely honest I was never really concerned that Oncosil would go up much higher. Of course as a long term holder I would want it to go higher. But it’s history is important to look at. Retail holders have had a terrible time with this stock for many many years. The stock price is lower today than last year. Broker reports predicted share price of circa 40 cents have also been wrong for many years.

I think many on this forum would agree that this company’s performance has been very disappointing. And I’m being polite here. Some on this forum will have a few more choice words to say.

The other point I would like to make is that management appear to be more concerned with the “scientific” achievements of the Oncosil device. As important as these achievements are, and I know they are important, the share price and returns are also important to shareholders. Let’s repeat what the share price is today. 12 cents. Let that sink in management. It’s 12 cents. Not 20 cents, Not 30 cents nor those 40 cent projections from the Brokers.

This is unsatisfactory from a shareholder perspective. Most of us are not scientists but rather passive investors who have spent a long long time with this company with virtually zero return for years. Again let that sink in. Zero return for years. No dividends, no capital gains, nothing.

Some people will say, we’ll sell up and go. That is a cop out. Shareholders deserve better. Zero returns, year in year out and asked to contribute to 2 capital raisings is not a good enough outcome. Particularly, when many bio tech stocks have been treated and are booming. A number of these biotech stocks have seen large share price increases without producing any revenue. Why is this position different at Oncosil?????

Expand

The share price languishing is more to do with Covid preventing them from commercialisation don't you thing? Progress is slow and capital has been raised along the way which is typical of this business. I do believe patience will be rewarded soon. GLTAH and respect management for their achievements to date either way.

OSL Price at posting: 12.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

1 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

There are more pages in this discussion • 56 more messages in this thread...

First 59 Last

Add OSL (ASX) to my watchlist

(20min delay)
Last 1.5¢		Change 0.002(15.4%)		Mkt cap ! $56.76M

Open	High	Low	Value	Volume
1.3¢	1.5¢	1.3¢	$76.04K	5.442M

Buyers (Bids)

No.	Vol.	Price($)
2	450000	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	9713598	7

View Market Depth

No.	Vol.	Price($)
2	450000	0.014
12	9692597	0.013
16	8588749	0.012
22	11107036	0.011
18	11258634	0.010

Price($)	Vol.	No.
0.015	9713598	7
0.016	4183334	3
0.017	5088882	2
0.018	1532208	3
0.019	200000	1

Last trade - 16.10pm 27/09/2024 (20 minute delay)

OSL (ASX) Chart

OSL Chart, page-59

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

OSL Chart, page-59

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News